RAS(ON) inhibition alters the tumor microenvironment in PDAC, highlighting T-cell interactions in treatment effectiveness.
Supplementary Figure S5: RAS(ON) multi-selective inhibition alters the PDAC tumor immune microenvironment
No takes yet. Share an insight, caveat, or question.
Orlen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: